Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Obesity | Research

Non-alcoholic fatty liver disease in hemochromatosis probands with iron overload and HFE p.C282Y/p.C282Y

Authors: James C. Barton, J. Clayborn Barton, Ronald T. Acton

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The aim of this study was to identify characteristics of non-alcoholic fatty liver disease (NAFLD) in adults with HFE p.C282Y/p.C282Y.

Methods

We retrospectively studied non-Hispanic white hemochromatosis probands with iron overload (serum ferritin (SF) > 300 µg/L (M), > 200 µg/L (F)) and p.C282Y/p.C282Y at non-screening diagnosis who did not report alcohol consumption > 14 g/d, have cirrhosis or other non-NAFLD liver disorders, use steatogenic medication, or have diagnoses of heritable disorders that increase NAFLD risk. We identified NAFLD-associated characteristics using univariate and multivariable analyses.

Results

There were 66 probands (31 men, 35 women), mean age 49 ± 14 (SD) y, of whom 16 (24.2%) had NAFLD. The following characteristics were higher in probands with NAFLD: median SF (1118 µg/L (range 259, 2663) vs. 567 µg/L (247, 2385); p = 0.0192); prevalence of elevated ALT/AST (alanine/aspartate aminotransferase) (43.8% vs. 10.0%; p = 0.0056); and prevalence of type 2 diabetes (T2DM) (31.3% vs. 10.0%; p = 0.0427). Mean age, sex, and prevalences of human leukocyte antigen-A*03 positivity, body mass index ≥ 30.0 kg/m2, hyperlipidemia, hypertension, and metabolic syndrome in probands with/without NAFLD did not differ significantly. Logistic regression on NAFLD using variables SF, elevated ALT/AST, and T2DM revealed: SF (p = 0.0318; odds ratio 1.0–1.0) and T2DM (p = 0.0342; 1.1–22.3). Median iron removed to achieve iron depletion (QFe) in probands with/without NAFLD did not differ significantly (3.6 g (1.4–7.2 g) vs. 2.8 g (0.7–11.0 g), respectively; p = 0.6862).

Conclusions

NAFLD in hemochromatosis probands with p.C282Y/p.C282Y is associated with higher median SF and greater T2DM prevalence, after adjustment for other factors. NAFLD does not influence QFe significantly.
Appendix
Available only for authorised users
Literature
2.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.PubMedCrossRef Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.PubMedCrossRef
3.
go back to reference Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198–210.PubMedCrossRef Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198–210.PubMedCrossRef
4.
go back to reference Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408.PubMedCrossRef Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408.PubMedCrossRef
5.
go back to reference Barton JC, Edwards CQ, Acton RT. HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene. 2015;574:179 – 92. Barton JC, Edwards CQ, Acton RT. HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene. 2015;574:179 – 92.
7.
go back to reference Edwards CQ, Barton JC. Hemochromatosis. In: Greer JP, Rodgers GM, Glader B, Arber DA, Means RT Jr, List AF, et al. editors. Wintrobe’s clinical hematology. Philadelphia: Wolters Kluwer; 2019. pp. 665–90. Edwards CQ, Barton JC. Hemochromatosis. In: Greer JP, Rodgers GM, Glader B, Arber DA, Means RT Jr, List AF, et al. editors. Wintrobe’s clinical hematology. Philadelphia: Wolters Kluwer; 2019. pp. 665–90.
8.
go back to reference Barton JC, McLaren CE, Chen WP, Ramm GA, Anderson GJ, Powell LW, et al. Cirrhosis in hemochromatosis: independent risk factors in 368 HFE p.C282Y homozygotes. Ann Hepatol. 2018;17:871–9.PubMedPubMedCentralCrossRef Barton JC, McLaren CE, Chen WP, Ramm GA, Anderson GJ, Powell LW, et al. Cirrhosis in hemochromatosis: independent risk factors in 368 HFE p.C282Y homozygotes. Ann Hepatol. 2018;17:871–9.PubMedPubMedCentralCrossRef
9.
go back to reference Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood. 2008;111:4456–62.PubMedCrossRef Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood. 2008;111:4456–62.PubMedCrossRef
10.
go back to reference Martin M, Millan A, Ferraro F, Tetzlaff WF, Lozano CE, Botta E et al. Leukocyte telomere length is associated with iron overload in male adults with hereditary hemochromatosis.Biosci Rep. 2020;40. Martin M, Millan A, Ferraro F, Tetzlaff WF, Lozano CE, Botta E et al. Leukocyte telomere length is associated with iron overload in male adults with hereditary hemochromatosis.Biosci Rep. 2020;40.
11.
go back to reference Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769–78.PubMedCrossRef Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769–78.PubMedCrossRef
12.
go back to reference Barton JC, Acton RT, Dawkins FW, Adams PC, Lovato L, Leiendecker-Foster C, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005;9:231–41.PubMedCrossRef Barton JC, Acton RT, Dawkins FW, Adams PC, Lovato L, Leiendecker-Foster C, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005;9:231–41.PubMedCrossRef
13.
go back to reference Bowman SA, Friday JE, Thoerig RC, Moshfegh AJ. Food Patterns Equivalents Database 2011-12: Methodology and User Guide [Online]. Food Surveys Research Group, Beltsville Human Nutrition Research Center, Agricultural Research Service, U. S. Department of Agriculture, Beltsville, Maryland. http://www.ars.usda.gov/nea/bhnrc/fsrg. Accessed 2 Jul 2022. Bowman SA, Friday JE, Thoerig RC, Moshfegh AJ. Food Patterns Equivalents Database 2011-12: Methodology and User Guide [Online]. Food Surveys Research Group, Beltsville Human Nutrition Research Center, Agricultural Research Service, U. S. Department of Agriculture, Beltsville, Maryland. http://​www.​ars.​usda.​gov/​nea/​bhnrc/​fsrg. Accessed 2 Jul 2022.
15.
go back to reference Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219–38.PubMedPubMedCentralCrossRef Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219–38.PubMedPubMedCentralCrossRef
16.
go back to reference Xia MF, Bian H, Gao X. NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol. 2019;10:877.PubMedPubMedCentralCrossRef Xia MF, Bian H, Gao X. NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol. 2019;10:877.PubMedPubMedCentralCrossRef
17.
go back to reference Barton JC. Hemochromatosis, HFE C282Y homozygosity, and bariatric surgery: report of three cases. Obes Surg. 2004;14:1409–14.PubMedCrossRef Barton JC. Hemochromatosis, HFE C282Y homozygosity, and bariatric surgery: report of three cases. Obes Surg. 2004;14:1409–14.PubMedCrossRef
18.
go back to reference Barton JC, Barton JC, Acton RT. HLA-A*03, the hemochromatosis ancestral haplotype, and phenotypes of referred hemochromatosis probands with HFE p.C282Y homozygosity. Hereditas. 2022;159:25.PubMedPubMedCentralCrossRef Barton JC, Barton JC, Acton RT. HLA-A*03, the hemochromatosis ancestral haplotype, and phenotypes of referred hemochromatosis probands with HFE p.C282Y homozygosity. Hereditas. 2022;159:25.PubMedPubMedCentralCrossRef
19.
go back to reference Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the study of Liver Diseases. Hepatology. 2011;54:328–43.PubMedCrossRef Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the study of Liver Diseases. Hepatology. 2011;54:328–43.PubMedCrossRef
20.
go back to reference Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.PubMedCrossRef Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.PubMedCrossRef
21.
23.
go back to reference Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726–36.PubMedCrossRef Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726–36.PubMedCrossRef
24.
go back to reference Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.PubMedCrossRef Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.PubMedCrossRef
25.
go back to reference Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–4.PubMedCrossRef Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–4.PubMedCrossRef
26.
go back to reference Chin J, Powell LW, Ramm LE, Hartel GF, Olynyk JK, Ramm GA. Utility of serum biomarker indices for staging of hepatic fibrosis before and after venesection in patients with hemochromatosis caused by variants in HFE. Clin Gastroenterol Hepatol. 2021;19:1459–68.PubMedCrossRef Chin J, Powell LW, Ramm LE, Hartel GF, Olynyk JK, Ramm GA. Utility of serum biomarker indices for staging of hepatic fibrosis before and after venesection in patients with hemochromatosis caused by variants in HFE. Clin Gastroenterol Hepatol. 2021;19:1459–68.PubMedCrossRef
28.
go back to reference Acton RT, Barton JC, Barton JC. Serum ferritin, insulin resistance, and metabolic syndrome: clinical and laboratory associations in 769 non-hispanic whites without diabetes mellitus in the HEIRS Study. Metab Syndr Relat Disord. 2015;13:57–63.PubMedPubMedCentralCrossRef Acton RT, Barton JC, Barton JC. Serum ferritin, insulin resistance, and metabolic syndrome: clinical and laboratory associations in 769 non-hispanic whites without diabetes mellitus in the HEIRS Study. Metab Syndr Relat Disord. 2015;13:57–63.PubMedPubMedCentralCrossRef
29.
go back to reference American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:14–S31.CrossRef American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:14–S31.CrossRef
30.
go back to reference Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745–9.PubMedCrossRef Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745–9.PubMedCrossRef
31.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
32.
33.
go back to reference Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710–8.PubMedCrossRef Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710–8.PubMedCrossRef
34.
go back to reference Ye Q, Qian BX, Yin WL, Wang FM, Han T. Association between the HFE C282Y, H63D polymorphisms and the risks of non-alcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma: an updated aystematic review and meta-analysis of 5,758 cases and 14,741 controls. PLoS ONE. 2016;11:e0163423.PubMedPubMedCentralCrossRef Ye Q, Qian BX, Yin WL, Wang FM, Han T. Association between the HFE C282Y, H63D polymorphisms and the risks of non-alcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma: an updated aystematic review and meta-analysis of 5,758 cases and 14,741 controls. PLoS ONE. 2016;11:e0163423.PubMedPubMedCentralCrossRef
35.
go back to reference Phatak PD, Barton JC. Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients. Hematology. 2003;8:429–32.PubMedCrossRef Phatak PD, Barton JC. Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients. Hematology. 2003;8:429–32.PubMedCrossRef
36.
go back to reference Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005;129:1937–43.PubMedCrossRef Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005;129:1937–43.PubMedCrossRef
37.
go back to reference Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10.PubMedPubMedCentralCrossRef Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10.PubMedPubMedCentralCrossRef
38.
go back to reference Abbas MA, Abraham D, Kushner JP, McClain DA. Anti-obesity and pro-diabetic effects of hemochromatosis. Obes (Silver Spring). 2014;22:2120–2.CrossRef Abbas MA, Abraham D, Kushner JP, McClain DA. Anti-obesity and pro-diabetic effects of hemochromatosis. Obes (Silver Spring). 2014;22:2120–2.CrossRef
39.
go back to reference Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker-Foster C, Rogowski J, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the atherosclerosis risk in Communities (ARIC) Study. Transl Res. 2008;152:3–10.PubMedPubMedCentralCrossRef Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker-Foster C, Rogowski J, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the atherosclerosis risk in Communities (ARIC) Study. Transl Res. 2008;152:3–10.PubMedPubMedCentralCrossRef
40.
go back to reference Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.PubMedCrossRef Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.PubMedCrossRef
41.
go back to reference Tokita Y, Maejima Y, Shimomura K, Takenoshita S, Ishiyama N, Akuzawa M, et al. Non-alcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men and women. Intern Med. 2017;56:763–71.PubMedPubMedCentralCrossRef Tokita Y, Maejima Y, Shimomura K, Takenoshita S, Ishiyama N, Akuzawa M, et al. Non-alcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men and women. Intern Med. 2017;56:763–71.PubMedPubMedCentralCrossRef
42.
go back to reference Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75:275–84.PubMedCrossRef Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75:275–84.PubMedCrossRef
43.
go back to reference Kasper P, Martin A, Lang S, Demir M, Steffen HM. Hypertension in NAFLD: an uncontrolled burden. J Hepatol. 2021;74:1258–60.PubMedCrossRef Kasper P, Martin A, Lang S, Demir M, Steffen HM. Hypertension in NAFLD: an uncontrolled burden. J Hepatol. 2021;74:1258–60.PubMedCrossRef
44.
go back to reference Ellervik C, Tybjaerg-Hansen A, Appleyard M, Ibsen H, Nordestgaard BG. Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy. J Intern Med. 2010;268:252–64.PubMedCrossRef Ellervik C, Tybjaerg-Hansen A, Appleyard M, Ibsen H, Nordestgaard BG. Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy. J Intern Med. 2010;268:252–64.PubMedCrossRef
45.
go back to reference Adams PC, Pankow JS, Barton JC, Acton RT, Leiendecker-Foster C, McLaren GD, et al. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: the hemochromatosis and Iron overload screening study. Circ Cardiovasc Genet. 2009;2:34–7.PubMedCrossRef Adams PC, Pankow JS, Barton JC, Acton RT, Leiendecker-Foster C, McLaren GD, et al. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: the hemochromatosis and Iron overload screening study. Circ Cardiovasc Genet. 2009;2:34–7.PubMedCrossRef
46.
go back to reference Barton JC, Barton JC, Adams PC, Acton RT. Risk factors for insulin resistance, metabolic syndrome, and diabetes in 248 HFE C282Y homozygotes identified by population screening in the HEIRS Study. Metab Syndr Relat Disord. 2016;14:94–101.PubMedPubMedCentralCrossRef Barton JC, Barton JC, Adams PC, Acton RT. Risk factors for insulin resistance, metabolic syndrome, and diabetes in 248 HFE C282Y homozygotes identified by population screening in the HEIRS Study. Metab Syndr Relat Disord. 2016;14:94–101.PubMedPubMedCentralCrossRef
48.
go back to reference Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17:95.PubMedPubMedCentralCrossRef Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17:95.PubMedPubMedCentralCrossRef
49.
go back to reference Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77–85.PubMedCrossRef Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77–85.PubMedCrossRef
50.
go back to reference Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. Am J Respir Crit Care Med. 2019;199:830–41.PubMedPubMedCentralCrossRef Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. Am J Respir Crit Care Med. 2019;199:830–41.PubMedPubMedCentralCrossRef
51.
go back to reference Lonardo A, Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity? Dig Liver Dis. 2019;51:462–70.PubMedCrossRef Lonardo A, Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity? Dig Liver Dis. 2019;51:462–70.PubMedCrossRef
52.
go back to reference Manka P, Bechmann L, Best J, Sydor S, Claridge LC, Coombes JD, et al. Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis. Dig Dis Sci. 2019;64:2351–8.PubMedCrossRef Manka P, Bechmann L, Best J, Sydor S, Claridge LC, Coombes JD, et al. Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis. Dig Dis Sci. 2019;64:2351–8.PubMedCrossRef
53.
go back to reference Itoh E, Hizuka N, Fukuda I, Takano K. Metabolic disorders in adult growth hormone deficiency: a study of 110 patients at a single institute in Japan. Endocr J. 2006;53:539–45.PubMedCrossRef Itoh E, Hizuka N, Fukuda I, Takano K. Metabolic disorders in adult growth hormone deficiency: a study of 110 patients at a single institute in Japan. Endocr J. 2006;53:539–45.PubMedCrossRef
Metadata
Title
Non-alcoholic fatty liver disease in hemochromatosis probands with iron overload and HFE p.C282Y/p.C282Y
Authors
James C. Barton
J. Clayborn Barton
Ronald T. Acton
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02763-x

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.